The Ion AmpliSeq Microbiome Health Research Assay (MHRA) is a next-generation sequencing (NGS) assay that allows for cost-effective yet comprehensive profiling of microbial diversity in the human gut microbiome. This new assay offers increased resolution and specificity of species-level detection compared with traditional 16S rRNA sequencing for key organisms associated with immunological response to cancer, diabetes and autoimmune diseases, gastrointestinal (GI) disorders, and infectious diseases.
Most other commercially available 16S panels target two to four hypervariable (HV) regions of the 16S rRNA gene, while the panel included with the MHRA targets eight out of the nine HV regions in addition to a set of high-resolution markers for increased species-level identification for highly comprehensive and sensitive microbial profiling research.
This larger targeted NGS panel, combined with a fully integrated data analysis tools, create a complete end-to-end solution to help both expand and simplify your microbiome research. Two versions of the MHRA are available, one on the Ion GeneStudio System, and the other on the Ion Torrent Genexus System, and these two versions of the assay take advantage of the different benefits offered by each NGS platform.
The Ion GeneStudio S5 System is a flexible, scalable, targeted NGS workhorse with wide application breadth and throughput capability. It’s ideal for labs looking for a cost-efficient NGS solution. You can perform MHRA on up to 48 samples per Ion 550 chip or choose the chip that fits your needs with an end-to-end, nucleic acid-to-report turnaround time of 48 hours.
Running the Ion AmpliSeq Microbiome Health Research Assay GX on the Genexus Integrated Sequencer is ideal for labs that are new to in-house NGS and want to leverage the highly automated workflow. Using the GX7 Chip, customers can run 24 samples in 2 lanes with only 10 minutes of hands-on time and a total turnaround time of 30 hours.
This webinar explores research into the potential impact of the gut microbiome on host response to SARS-CoV-2 as well as the efficacy of various immune interventions such as future vaccines.
This poster introduces a first-of-its-kind targeted sequencing solution for a cohort of bacteria associated with immune responses to cancer immunotherapy, gastrointestinal/autoimmune disorders, and infectious diseases such as SARS-CoV-2 infection.
Using stool samples, we show high reproducibility from experiment to experiment (Figure 2).
Recently, the SARS-CoV-2 virus has highlighted the potential influence that the commensal gut microbiome has on infection as well as severity of infection. There have been many studies looking at the possible impact that a disruption of gut diversity has on SARS-CoV-2 infection and how diversity and abundance of key species may play a role in vaccine research and efficacy. Targeted NGS utilizing the MHRA is a simple and pertinent tool to understand and characterize microbe mediation of infectious diseases as well as immune health and treatment research.
The MHRA also offers a complete end-to-end, nucleic acid-to-report solution, with an optimized analysis workflow using Ion Reporter Software for analysis of data generated with the Ion GeneStudio system or embedded in the Genexus Software when using the Genexus System. The analysis workflow enables multi-sample analysis and visualization, such as heatmap, PCoA, relative abundance, and diversity visualization. The analysis uses up-to-date reference databases such as the curated SILVA database, the Applied Biosystems MicroSeq database, Greengenes, and NCBI.
What's in our gut effects our health
Hugo Roume of the French National Institute for Agricultural Research discusses the role of the microbiome in human health ›
SITC 2020 - Ion AmpliSeq Microbiome Health Research Kit
Introduction to the new Ion AmpliSeq Microbiome Health Research kit- high resolution species level microbiome profiling ›
For Research Use Only. Not for use in diagnostic procedures.